Disease Acronyms

Question 1

SMM

Answer 1

Smoldering Multiple Myeloma

Question 2

NDMM

Answer 2

Newly Diagnosed Multiple Myeloma

Question 3

TE NDMM

Answer 3

Transplant Eligible Newly Diagnosed Multiple Myeloma

Question 4

TIE NDMM

Answer 4

Transplant Ineligible Newly Diagnosed Multiple Myeloma

Question 5

RRMM

Answer 5

Relapsed/Refractory Multiple Myeloma

Question 6

RR or R/R

Answer 6

Relapsed/Refractory

Question 7

Relapsed

Answer 7

Responded but stopped responding after 6 months

Question 8

Refractory

Answer 8

Does not result in remission or gets worse within six months.

Question 9

Overall Survival (OS)

Answer 9

Duration of patient survival from time of initial treatment.

Question 10

Progression Free Survival (PFS)

Answer 10

The time from treatment initiation to progression/worsening of the disease

Question 11

Complete Response (CR)

Answer 11

Absence of all detectable cancer following completion of treatment

Question 12

Stringent Complete Response (SCr)

Answer 12

In addition to absence of all detectable cancer following completion of treatment, patient has:

1) normal free light chain ratio in serum and
2) absence of clonal cells in the bone marrow

Question 13

Light Chains

Answer 13

Proteins produced by plasma cells which link to heavy chains to produce immunoglobulins.

Question 14

Immunoglobulins

Answer 14

Antibodies

Question 15

Free Light Chains (FLC) or Serum Free Light Chains (SFLC)

Answer 15

Light Chains that are not part of whole immunoglobulins and are present in the blood

Question 16

Partial Response (PR)

Answer 16

1) At least 50% reduction in serum monoclonal protein ; and

2) At least 90% reduction in 24-hour urine monoclonal protein, up to 200 mg/ 24h

Question 17

Very Good Partial Response (VGPR)

Answer 17

1) Monoclonal protein levels detectable by immunofixation, but not on electrophoresis, in serum and urine;
2) At least 90% reduction in serum monoclonal protein; and
3) monoclonal protein level in urine <100mg/24h

Question 18

Overall Response Rate (ORR)

Answer 18

Sum of SCr, CR, PR, and VGPR.

Question 19

Electrophoresis

Answer 19

Separation of proteins based on physical properties, and using subsets of these proteins to interpret results of multiple myeloma test.

Question 20

Immunofixation

Answer 20

Tests that determine levels of monoclonal protein

Question 21

Minimal Residual Disease (MRD)

Answer 21

Presence of a small number of myeloma cells in body after responding well to therapy.

Question 22

Duration of Response (DOR)

Answer 22

Length of time disease/cancer remains in remission after treatment.

Question 23

How is Duration of Response (DOR) calculated?

Answer 23

From time of first recorded achievement of particular response level.

Question 24

Time to Disease Progression (TTP)

Answer 24

Time from randomization until objective tumor progression, excluding death.

Question 25

Median Follow Up (mFU)

Answer 25

Median time between a specific event and when outcomes data are collected